Top

Pipeline

Scroll Down

Lantern Pharma Oncology Drug Portfolio

Scroll Down

Taking a novel approach to drug development

Pipeline

Lantern’s current portfolio consists of three lead drug candidates and an ADC program across 12 cancer indications, including onelead product candidate in phase 2 clinical testing and recently initiated phase 1 clinical programs for two additional lead product candidates. Lantern believes that the use of machine learning, genomics and computational methods can help accelerate the development and commercialization of small molecule-based therapies. These drugs can be targeted to patients whose genomic profile identifies them as having the highest probability of benefiting from the drug, thereby creating the potential to achieve better outcomes.

Lantern Pharma Oncology Pipeline

By clicking “Accept All”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. View our Privacy Policy for more information.